ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma, Systemic"

  • Abstract Number: 0545 • ACR Convergence 2021

    SIRT1 Modulates the Senescent Phenotype in Scleroderma Endothelial Cells

    Ellen Model, Morgan Omara, Pamela Palisoc, Dinesh Khanna and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI

    Background/Purpose: Vascular abnormalities in systemic sclerosis (SSc) are characterized by injury to vascular wall and extensive damage of the microvessels. It has been shown that…
  • Abstract Number: 1390 • ACR Convergence 2021

    A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis

    Alicia Hinze1, Shreyasee Amin1, Ashima Makol1, Robert Vassallo1, Cynthia Crowson2 and Brian Bartholmai1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN

    Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable. Some patients experience a progressive decline in lung function…
  • Abstract Number: 0546 • ACR Convergence 2021

    Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis

    Kristina Clark1, Eszter Csomor2, Corrado Campochiaro3, Adam Taylor4, Yee Voan Teo2, Katherine Nevin2, Mary Morse2, Voon Ong5, Emma Derrett-Smith6, Nicolas Wisniacki2, Shaun Flint2 and Christopher Denton7, 1University College London, London, United Kingdom, 2GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 3Royal Free Hospital London, London, United Kingdom, 4GlaxoSmithKline, London, United Kingdom, 5University College London Medical School Royal Free Campus, London, United Kingdom, 6University College London Division of Medicine, London, United Kingdom, 7University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…
  • Abstract Number: 1437 • ACR Convergence 2021

    Fat and Fibrosis: A Novel Developmental Gene in Systemic Sclerosis

    Nancy Wareing1, Brian Skaug2, Minghua Wu3, Scott Collum1, Cory Wilson1, Lucy Revercomb4, Marka Lyons5, Weizhen Bi6, Tingting Mills1, Julio Charles5, Shervin Assassi1 and Harry Karmouty-Quintana1, 1University of Texas McGovern Medical School at Houston, Houston, TX, 2University of Texas McGovern Medical School Houston, Houston, TX, 3University of Texas Health Science Center at Houston, Houston, TX, 4Rice University, Houston, TX, 5Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, 6McGovern Medical School at UTHealth, Houston, TX

    Background/Purpose: Early loss of skin-associated adipose tissue and concomitant replacement by extracellular matrix is a hallmark of systemic sclerosis (SSc). However, the contribution of adipose…
  • Abstract Number: 0548 • ACR Convergence 2021

    Rapamycin Blocks the Profibrotic Effects of Fli1 Downregulation in Scleroderma Myeloid Cells

    Fatima El-adili, Grace Marden, Maria Trojanowska and Andreea Bujor, Boston University School of Medicine, Boston, MA

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune fibrotic disease with unclear pathogenesis and no effective therapies. Increased proportion of CD163-positive, profibrotic macrophages has been described…
  • Abstract Number: 1836 • ACR Convergence 2021

    Outcomes Linked to Eligibility for Stem Cell Transplantation Trials in Diffuse Cutaneous Systemic Sclerosis

    Julia Spierings1, Svetlana Nihtyanova2, Emma Derrett-Smith3, Kristina Clark2, Jacob van Laar4, Voon Ong5 and Christopher Denton6, 1University Medical Center Utrecht, Utrecht, Netherlands, 2University College London, Royal Free Campus, London, United Kingdom, 3University College London Division of Medicine, London, United Kingdom, 4University Medical Centre Utrecht, Utrecht, Netherlands, 5University College London Medical School Royal Free Campus, London, United Kingdom, 6University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Autologous haematopoietic stem cell transplantation (SCT) has emerged as an effective treatment for patients with severe diffuse systemic sclerosis (dcSSc) based upon the results…
  • Abstract Number: 0552 • ACR Convergence 2021

    Long Non-coding RNA H19X as a Regulator of Endothelial Adhesion Molecules in Systemic Sclerosis

    Francesca Tirelli1, Elena Pachera1, Robert Lafyatis2, Menqi Huang3, Francesco Zulian4, Gabriela Kania1 and Oliver Distler5, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2University of Pittsburgh, Pittsburgh, PA, 3Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 4Rheumatology Unit, Department of Woman and Child Health - University of Padova, Padova, Italy, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland

    Background/Purpose: Long non-coding RNAs (lncRNAs) are non-coding transcripts involved in the regulation of gene expression; their role in disease development, to date, remains largely under…
  • Abstract Number: 1843 • ACR Convergence 2021

    Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort

    Jessica Gordon1, Kimberly Showalter1, Yin Wu2, Linda Kwakkenbos3, Marie-Eve Carrier4, Richard Henry2, Nora Østbø2, Julia Nordlund2, Angelica Bourgeault2, Mara Canedo Ayala2, Marie-Nicole Discepola2, Andrea Carboni Jiménez2, Christopher Denton5, Luc Mouthon6, Brett Thombs7 and Robert Spiera1, 1Hospital for Special Surgery, New York, NY, 2Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, 3Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, 4Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, 5University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 6Hopital Cochin - Paris University, Paris, France, 7Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada

    Background/Purpose: Hesitancy about COVID-19 vaccination exists among patients with rheumatic and musculoskeletal diseases, but previous studies have not assessed this specifically in patients with systemic…
  • Abstract Number: 0553 • ACR Convergence 2021

    IgG from Systemic Sclerosis Patients Induce a Profibrosing and Serotype-dependent Phenotype in Normal Dermal Fibroblast: A Multi-omics Study

    Aurélien Chepy1, Solange Vivier2, Fabrice Bray3, Martin Figeac4, Jean-Pascal Meneboo4, Camille Ternynck5, Lucile Guilbert2, Manel Jendoubi2, Christian Rolando3, David Launay1, Sylvain Dubucquoi6, Guillemette Marot5 and Vincent Sobanski1, 1Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille, France, 2Univ. Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, F59000 Lille, France, Lille, France, 3Univ. Lille, CNRS, USR 3290 - MSAP - Miniaturisation pour la Synthèse, l'Analyse et la Protéomique, F-59000 Lille, France, Lille, France, 4Université de Lille, Functional Genomics Platform, Lille, France., Lille, France, 5ULR 2694 – METRICS : évaluation des technologies de santé et des pratiques médicales, université de Lille, CHU de Lille, 59000 Lille, France, Lille, France, 6Univ. Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, F59000 Lille, France, Lille

    Background/Purpose: Antinuclear antibodies are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is much more debated. This study explored the…
  • Abstract Number: 1847 • ACR Convergence 2021

    Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis

    Elizabeth Volkmann1, Donald Tashkin2, Mei Leng2, Grace Kim2, Jonathan Goldin2 and Michael Roth2, 1Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Esophageal dysmotility is a common feature of systemic sclerosis (SSc) and aspiration of gastric contents may serve as an inciting and/or exacerbating factor in…
  • Abstract Number: 0383 • ACR Convergence 2020

    Sex Differences in Severity and Progression of Interstitial Lung Disease in Systemic Sclerosis: What We Have Learned from Clinical Trials

    Elizabeth Volkmann1, Ning Li2, Michael Roth2, Carol Feghali-Bostwick3, Richard Silver4, DeAnna Baker Frost5, Shervin Assassi6, Grace Kim2, Jonathan Goldin2 and Donald Tashkin2, 1University of California, Los Angeles, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles, 3The Medical University of South Carolina, Charleston, SC, 4Medical University of South Carolina, Charleston, 5The Medical University of South Carolina, Charleston, 6University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX

    Background/Purpose: Although systemic sclerosis (SSc) disproportionately affects females compared with males [1], observational studies have demonstrated higher mortality rates in males with SSc [2]. This…
  • Abstract Number: 1172 • ACR Convergence 2020

    Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma

    Gloria Lanzoni1, Giorgia Martini1, Alessandra Meneghel1, Fabio Vittadello2, Biagio Castaldi1, Elisabetta Zanatta3 and Francesco Zulian1, 1Department of Woman's and Child's Health, University of Padova, Padua, Italy, 2Centro Studi Statistici Explora, Padua, Italy, 3Department of Medicine-DIMED, University of Padova, Padua, Italy

    Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare condition in childhood and its variety with no skin involvement, systemic sclerosis sine scleroderma (JSSSS) is anecdotal…
  • Abstract Number: 0384 • ACR Convergence 2020

    Serum Neutrophil Count Predicts Progression of Interstitial Lung Disease and Mortality in Patients with Systemic Sclerosis Related Interstitial Lung Disease

    Nancy Wareing1, Ning Li2, Elizabeth Volkmann3, Marka Lyons4, Michael Roth2, Donald Tashkin2 and Shervin Assassi1, 1University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, 2University of California, Los Angeles, Los Angeles, 3University of California, Los Angeles, Los Angeles, CA, 4University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX

    Background/Purpose: Systemic sclerosis (SSc) patients have a prominent neutrophil gene expression signature.  However, investigations into the pathophysiologic role of neutrophils in SSc are lacking. This…
  • Abstract Number: 1173 • ACR Convergence 2020

    No Disease Progression After 36 Months Follow up in the Juvenile Systemic Scleroderma Inception Cohort

    Ivan Foeldvari1, Jens Klotsche2, Ozgur Kasapcopur3, Amra Adrovic4, Maria Teresa Terreri5, Edoardo Marrani6, Tadej Avcin7, Maria Katsicas8, Dana Nemcova9, Maria Jose Santos10, Jürgen Brunner11, Tilmann Kallinich12, Mikhail Kostik13, Kirsten Minden14, Anjali Patwardhan15, Kathryn Torok16 and Nicola Helmus17, 1Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, 2German Rheumatism Research Center, Berlin, Germany, 3PRINTO, Istituto Giannina Gaslini, Genova, Italy, 4Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, 5Federal University of São Paulo, São Paulo, Brazil, 6University of Florence, Firenze, Italy, 7Ljubljana University Medical Centre, Ljubljana, Slovenia, 8Hospital de Pediatria, Buenos Aires, Argentina, 9General University Hospital, Prague, Czech Republic, 10Hospital Garcia de Orta, Almada, Portugal, 11Tirol Kliniken, Innsbruck, Innsbruck, Austria, 12Charite, Berlin, Germany, 13Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 14Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 15University of Missouri, Columbia, 16University of Pittsburgh, Pittsburgh, PA, 17Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany

    Background/Purpose: Juvenile systemic scleroderma (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. Longitudinal prospective follow up data of…
  • Abstract Number: 0392 • ACR Convergence 2020

    Prevalence and Survival of Systemic Sclerosis (SSc) and Associated Interstitial Lung Disease (ILD) in Ontario, Canada over 10 Years

    Janet Pope1, Kobina Quansah2, Martin Kolb3, Jason Flavin4, Hassan Shazia5 and Soo Jin Seung5, 1Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, 2Boehringer Ingelheim (Canada) Limited, Burlington, ON, Canada, 3McMaster University and Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamliton, ON, Canada, 4Boehringer Ingelheim, Corporate Headquarters, Burlington, ON, Canada, 5HOPE Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by skin thickening, vascular lesions and fibrotic changes in various organs, mainly the lungs, heart, intestinal…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology